139 related articles for article (PubMed ID: 8695876)
21. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
22. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
24. Expansion and activation of human natural killer cells as therapy for autologous transplantation.
Miller JS; Verfaillie C; McGlave P
Prog Clin Biol Res; 1994; 389():39-45. PubMed ID: 7700914
[No Abstract] [Full Text] [Related]
25. Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?
Kronenwett R; Haas R
Recent Results Cancer Res; 1998; 144():127-38. PubMed ID: 9304714
[No Abstract] [Full Text] [Related]
26. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study.
Luger SM; O'Brien SG; Ratajczak J; Ratajczak MZ; Mick R; Stadtmauer EA; Nowell PC; Goldman JM; Gewirtz AM
Blood; 2002 Feb; 99(4):1150-8. PubMed ID: 11830460
[TBL] [Abstract][Full Text] [Related]
27. BCR-ABL antisense purging in chronic myeloid leukaemia.
Kirkland MA; O'Brien SG; McDonald C; Davidson RJ; Cross NC; Goldman JM
Lancet; 1993 Sep; 342(8871):614. PubMed ID: 8102739
[No Abstract] [Full Text] [Related]
28. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.
Bishop MR; Warkentin PI; Jackson JD; Bayever E; Iversen PL; Whalen VI; Lastovica J; Haines K; Kessinger A
Prog Clin Biol Res; 1994; 389():183-7. PubMed ID: 7700901
[No Abstract] [Full Text] [Related]
30. Chronic myeloid leukaemia: a therapeutic challenge.
Mughal TI; Goldman JM
Ann Oncol; 1995 Sep; 6(7):637-44. PubMed ID: 8664183
[No Abstract] [Full Text] [Related]
31. Selection of BCR/ABL-negative progenitor cells from chronic myeloid leukemia marrow.
Leemhuis T; Leibowitz D; Cox G; Srour EF; Tricot G; Hoffman R
Prog Clin Biol Res; 1992; 377():231-7. PubMed ID: 1279706
[No Abstract] [Full Text] [Related]
32. Chronic myeloid leukaemia: potential for antisense therapy.
Lancet; 1992 Nov; 340(8830):1262-3. PubMed ID: 1359327
[No Abstract] [Full Text] [Related]
33. Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia.
O'Brien SG; Goldman JM
J Clin Oncol; 1995 Mar; 13(3):541-6. PubMed ID: 7884413
[No Abstract] [Full Text] [Related]
34. Specificity of BCR-ABL antisense oligonucleotides.
Smetsers TF; Mensink EJ
Blood; 1995 Jan; 85(2):597-8. PubMed ID: 7812014
[No Abstract] [Full Text] [Related]
35. Long-term culture of autologous bone marrow for marrow reconstitution following high-dose chemotherapy. Purging with tumor surface antigen directed human-human monoclonal antibody.
Alonso K; Medenica R; Morehead G
Prog Clin Biol Res; 1994; 389():111-8. PubMed ID: 7700892
[No Abstract] [Full Text] [Related]
36. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
37. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
[TBL] [Abstract][Full Text] [Related]
38. BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
Cotter TG
Leuk Lymphoma; 1995 Jul; 18(3-4):231-6. PubMed ID: 8535187
[TBL] [Abstract][Full Text] [Related]
39. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.
Clark RE; Grzybowski J; Broughton CM; Pender NT; Spiller DG; Brammer CG; Giles RV; Tidd DM
Bone Marrow Transplant; 1999 Jun; 23(12):1303-8. PubMed ID: 10414920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
